Why BGPT?
logo

Author Review Workspace

Draft versioned claims from your manuscript with linked experiments, exact results, limitations, falsifiability notes, and provenance for reviewers.Know what the science actually supports before you trust the answer.

Press Enter ↵ to import


     Quick Explanation



    R Kogo scientific signal (from provided data): strong bibliometric footprint in cancer/oncology literature (OpenAlex top-match “Ryunosuke Kogo” shows h-index 17; cited_by_count 2901; works_count 86). Most directly verifiable publications in the dataset include high-impact venue work such as Nature Medicine () and Cancer Research ().
    Key limitation: the provided “R Kogo” could be multiple distinct people; the dataset includes several similarly named authors. I therefore assess strength primarily for the top OpenAlex match provided, not for every “R Kogo” string variant.



     Long Explanation



    Author Review: R Kogo

    Date context: April 09, 2026. Evidence scope: only what appears in your provided dataset (OpenAlex-like metrics, example DOIs, and one additional plant paper dataset). No uncited claims are added.
    Identity check (critical):
    Your provided data includes multiple potential matches for the query string “R Kogo” on OpenAlex (e.g., “Ryunosuke Kogo” with h-index 17; and “Reiri Kogo” with h-index 2, cited_by_count 67, works_count 4). This introduces name-collision risk: bibliometrics and publication lists may refer to different individuals.

    1) Bibliometric footprint (from provided OpenAlex top-match data)

    The strongest matched identity in your dataset is Ryunosuke Kogo (OpenAlex id shown in your data). Metrics provided: works_count = 86, cited_by_count = 2901, h-index = 17, and yearly counts also provided.
    Interpretation (skeptical): citation metrics can be skewed by field size, review/author position, venue effects, and older work accumulating citations (i.e., not a direct measure of rigor per paper).
    Notable anomaly from your provided data: a very large cited_by_count in 2011 (1626) alongside only 4 works. That pattern is plausible for a single highly cited paper, but it also can reflect how “counts_by_year” are mapped in your dataset (e.g., year of citation accumulation vs. year-of-publication). Treat this as data-structure dependent rather than direct biological or scientific inference.

    2) Example high-impact publications explicitly present in your dataset

    I list DOIs only as identity-linked evidence that an oncology-focused author profile exists in your provided data. I do not infer study outcomes, sample sizes, or conclusions beyond what is explicitly provided.
    DOI Title (as provided) Year / Venue (as provided) Authorship note (as provided)
    10.1158/0008-5472.can-11-1021 Long Noncoding RNA HOTAIR Regulates Polycomb-Dependent Chromatin Modification and Is Associated with Poor Prognosis in Colorectal Cancers 2011, Cancer Research Ryunosuke Kogo listed as first author in your OpenAlex excerpt
    10.1038/nm.2392 Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11 2011, Nature Medicine Ryunosuke Kogo appears among coauthors in your excerpt
    10.3892/or.2012.2219 Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma
    10.1158/1078-0432.ccr-10-2866 Clinical Significance of miR-146a in Gastric Cancer Cases 2011, Clinical Cancer Research Ryunosuke Kogo listed as first author in your excerpt
    Evidence objects above are supported by the DOI links below:

    3) Critical methodological lens (what we can and cannot conclude from the provided dataset)

    What is strong: your dataset provides bibliometric indicators (h-index, citations, works_count) and explicit DOIs for selected publications, enabling reproducible lookup.
    What is weak / missing: there is no full-text content for the listed cancer/oncology papers in your prompt, so I cannot evaluate experimental design quality (controls, blinding, replication, effect sizes), nor can I assess reproducibility or publication bias directly.
    Name-collision risk: “R Kogo” can refer to multiple authors. Without ORCID-level identity disambiguation for every included record, bibliometrics may be conflated.
    Counterpoint: citation counts reflect community attention and can be influenced by trendiness and venue. They do not automatically measure mechanistic correctness.

    4) Additional raw-data item you provided (plant polyphenols under salt stress)

    Your message includes a separate dataset describing a plant study about polyphenolics in Arabidopsis thaliana cat2 knockout under salt stress. This item is not linked to “R Kogo” identity in what you provided, so I treat it as an unresolved evidence fragment.
    The plant study is anchored by DOI 10.7124/visnyk.utgis.14.2.683 in your dataset. It states the Folin–Ciocalteu assay non-specificity limitation and the extracted design/timepoints.

    5) Overall scientific strength assessment (evidence-limited)

    • Bibliometric strength: for the top OpenAlex match in your dataset, metrics are consistent with an established oncology research contributor (h-index 17; 2901 citations; 86 works). (Metric values come from your provided data; not re-derived.)
    • Scientific uncertainty: because you did not provide full-text experimental details for the oncology publications, I cannot judge experimental rigor, statistical robustness, or mechanistic validity directly.
    • Primary blindspot: name ambiguity (multiple “R Kogo” matches) and missing full-text evidence prevent a confident, paper-by-paper quality audit.


    Feedback:   

    Updated: April 09, 2026

    BGPT Author Review



    Scientific Quality

    60%

    Moderately strong based on bibliometrics provided, but scientific quality is not directly verifiable from your prompt: there is no full-text experimental/statistical detail for the oncology papers. Name-collision risk (“R Kogo” variants) further reduces confidence; the assessment is therefore cautious and evidence-limited.



    Communication Quality

    60%

    Communication quality cannot be assessed from your prompt because abstracts/full texts and writing samples are not included. The provided item titles suggest familiarity with standard biomedical framing, but that’s not enough for a rigorous communication score.



    Author Novelty

    50%

    Novelty cannot be determined without reading the papers’ specific methodological and conceptual advances. High citation counts suggest impact, but impact ≠ novelty; dataset lacks content for evaluation.



    Scientific Rigor

    50%

    Rigor is not assessable here: no detailed methods, replicates, blinding, statistical plans, or preregistration are provided for the oncology examples. Only the separate plant-item excerpt includes some limitations (e.g., Folin–Ciocalteu non-specificity), but it is not tied to the author identity in your prompt.

     Analysis Wizard



    It downloads the author-linked DOI list, extracts methods/statistics from full texts, then scores rigor via a checklist and produces citation-weighted evidence tables for falsifiable conclusions.



     Hypothesis Graveyard



    “High h-index implies universally high experimental rigor” is unlikely to hold because citation metrics do not measure control quality, reproducibility, or statistical validity.


    “All oncology biomarkers proposed by a high-citation author are causal” is likely false in many contexts because correlation-driven biomarker pipelines often overfit without adequate causal and cross-cohort validation.

     Science Art


    Author Review: R Kogo Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT